Pitt St Research interview with Race Oncology’s CEO Phil Lynch & CSO Dr Daniel Tillett

26 Oct
Oct , 26 , 2022 Daniel Tillett
LinkedIn

Related posts:

Race Develops Improved IV Formulation of Zantrene Race Oncology ASX Small and Mid Cap Conference Presentation CSO Dr Daniel Tillett talks to Small Caps about Race Oncology’s Plans for 2022 and beyond